Patients with T2D and CKD have a very high risk of CV events. Listen as Dr. Jorge Plutzky and Dr. Neha Pagidipati discuss new therapies to manage cardiovascular and renal risk in patients with T2D. Their discussion is based on new science presented during AHA Scientific Sessions 2020.
2020 Episode 10 – Managing CV and Renal Risk in Patients with T2D
Jorge Plutzky, MD is the Director of Preventive Cardiology in the Cardiovascular Division at Brigham and Women’s Hospital (BWH) and on the faculty of Harvard Medical School. Dr. Plutzky’s clinical interests have focused on preventing all manifestations of cardiovascular disease, with a particular interest in the intersection between abnormal metabolism, like obesity, dyslipidemia and diabetes and cardiovascular health. The current Chair of the AHA’s Diabetes Committee and the recipient of numerous awards for teaching and research, he is also the principal investigator of an NIH-funded basic science laboratory investigating mechanisms of cardio-metabolic disorders.
Neha J. Pagidipati, MD, MPH is an Assistant Professor of Medicine and cardiovascular disease prevention specialist. Since 2011, she has conducted research on cardiometabolic disease prevention, lifestyle modification and weight management. She is also building the Duke Cardiometabolic Disease Prevention Program, which focuses on behavior change and risk factor management in patients with high risk of cardiovascular and metabolic diseases such as diabetes and obesity.